BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to...
BC Extra | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to...
BC Extra | Oct 4, 2019
Clinical News

Arbutus scuttles lead HBV capsid inhibitor program

Arbutus scrapped plans to start a combination trial next year due to the emergence of a safety signal in two healthy volunteers in a Phase I study of AB-506, an oral capsid inhibitor expected to...
BC Week In Review | Nov 30, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. (Atlanta, Ga.) raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De...
BC Extra | Nov 27, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De La Rosa...
BC Week In Review | Jul 27, 2018
Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
BC Extra | Jul 26, 2018
Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
BC Week In Review | Oct 6, 2017
Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of 1.2 million convertible preferred shares at a $7.13 conversion price, which represents a 15%...
BC Extra | Oct 2, 2017
Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of convertible preferred shares at a $7.13 conversion price, which represents a 15% premium to...
BC Week In Review | Sep 1, 2017
Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
Items per page:
1 - 10 of 404
BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to...
BC Extra | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to...
BC Extra | Oct 4, 2019
Clinical News

Arbutus scuttles lead HBV capsid inhibitor program

Arbutus scrapped plans to start a combination trial next year due to the emergence of a safety signal in two healthy volunteers in a Phase I study of AB-506, an oral capsid inhibitor expected to...
BC Week In Review | Nov 30, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. (Atlanta, Ga.) raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De...
BC Extra | Nov 27, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De La Rosa...
BC Week In Review | Jul 27, 2018
Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
BC Extra | Jul 26, 2018
Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
BC Week In Review | Oct 6, 2017
Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of 1.2 million convertible preferred shares at a $7.13 conversion price, which represents a 15%...
BC Extra | Oct 2, 2017
Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of convertible preferred shares at a $7.13 conversion price, which represents a 15% premium to...
BC Week In Review | Sep 1, 2017
Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
Items per page:
1 - 10 of 404